Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL
Upon determination of eligibility, patients will receive: * Arsenic Trioxide
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
41
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Overall response rate
Progression-free survival
Toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.